Studies revealed that vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) inhibitors may synergize with immunotherapy by reducing tumor angiogenesis, promoting vascular normalization, increasing oxygen delivery, and facilitating the infiltration of effector immune T cells (3). Here, VEGFA is linked to neoplasm.